Boston, MA 06/24/2014 (wallstreetpr) – OHR Pharmaceutical Inc (NASDAQ:OHRP), the pharmaceutical company which focuses on research and development in ophthalmology, announced hosting a conference call and webcast on June 24, 2014. The call is scheduled to be held on Tuesday, 8:30 p.m. Eastern Time.
Phase II Study Data
OHR Pharmaceutical Inc (NASDAQ:OHRP) seeks to discuss the results it has obtained from a Squalamine short-term Phase II study, which involves treatment of wet age related macular degeneration. Squalamine is an innovative eye drop formation of OHR Pharmaceuticals for treating wet-AMD. It is an anti-angiogenic small molecule demonstrating an innovative intracellular behavior. This mechanism counteracts several growth factors which are associated with the angiogenesis procedure.
The drug was administered in more than 250 patients intravenously in the first and second Phases of wet-AMD treatment. It exhibited favorable biological results and resulted in improved visual acuity in the observed patients.
Conference Call Details
The conference call can be accessed by dialing on the toll free number 877-407-0789. For international callers, the call will be available on 201-689-8562. In addition, a live webcast of the event can be viewed on OHR Pharmaceutical Inc (NASDAQ:OHRP)’s website. A repeat of the conference call, for those who miss the live event, will be available through July 8, 2014. To access the same, callers need to dial the toll free number 877-870-5176 and for international callers, the number is 858-384-5517. The required replay Pin to hear the repeat conference call is 13585479.
CCA Industries, Inc. (NYSEMKT:CAW) declined to comment on unusual market activity, saying it is not the company’s policy.
The New York Stock Exchange contacted the health and beauty products’ manufacturer as it noticed unusual market activity related to the company’s common stock traded on the NYSE MKT exchange. However, CAA Industries did not comment anything in this regards and stated that it is against the company’s policy to make any comments in such cases.
